Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.14% | 48.28 | 48.12 | 48.63 | 48.64 | 47.885 | 48.57 | 3,035,899 | 23:55:41 |
From Nov 2023 to Nov 2024
By Denny Jacob
Sanofi will terminate its proposed licensing agreement with Maze Therapeutics following opposition from the Federal Trade Commission.
The FTC on Monday said it would seek to block the healthcare company's proposed acquisition of an exclusive license to Maze's therapy in development for the treatment of Pompe disease. The regulator's complaint alleges the deal would protect Sanofi's monopoly and eliminate competition between Sanofi and Maze to develop new Pompe drugs.
Sanofi said it respectfully disagrees with the FTC's action and its partnership with Maze was designed to apply its resources to accelerate the development of MZE001.
"The delay associated with a long litigation has led Sanofi to conclude that it would not be in the best interests of patients to contest this litigation and Sanofi will therefore be terminating the agreement with Maze in accordance with its terms," Sanofi said.
The agreement between Sanofi and Maze for MZE001 was disclosed on May 1.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 11, 2023 17:03 ET (22:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
